Small Pharmaceuticals
Market Cap
₹16,954 ₹16,954 Cr.
P/E
101.77
PEG
7.54
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis comes live if test-kit volume scales within existing capacity and assay commercialization supports demand without material tender or customer delays.

The bull path combines faster kit-volume growth with stronger realization; the bear path reflects volume shortfall, weaker pricing, delayed commercialization and underused capacity.

Key Ratios

Debt to Equity
Debt to Equity
0.35
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
5.60 %
Institutions
Institutions
17.88 %
Market cap
Market cap
16,954 Cr
No. of Shareholders
No. of Shareholders
2.34 L
OPM (%)
OPM (%)
-
PE
PE
101
Prom Holding
Prom Holding
41.29 %
ROCE (%)
ROCE (%)
17.36
ROE (%)
ROE (%)
14.25
Sales
Sales
1,445 Cr
  • Molbio Diagnostics
  • Poly Medicure
  • Dr. Lal Pathlabs
Last updated on 12 Oct 2026
  • Molbio makes Truenat, a portable molecular point-of-care testing platform, with test kits and devices as its core. Radiology and digital pathology are secondary.
  • Truenat tests cover TB and other diseases. Molbio sells mainly to India's public TB program and to buyers in Africa and Southeast Asia.
  • Profit comes mainly from recurring Truenat test kits, about 75% of product revenue. Device sales are lumpy.
  • It is the second WHO-endorsed technology for TB point-of-care testing. Its closed devices from 2017-18 still run with no replacement cycle.
  • Molbio is adding automation and building an R&D centre with no major capex beyond that. It is entering new tests and geographies and seeking acquisitions.
  • FY27 depends on kit use, export timing and new test uptake. Management guides about 25% revenue growth and 24-25% EBITDA margin for FY27.
  • Receivables stay high and working capital is heavy. Past audits flagged control gaps that remain unresolved.
  • Screening test for HPV in ages 30-45 by Q2FY27 results
    it settles expected volumes, pricing and WHO prequalification progress.
  • New test rollout in Europe by Q2FY27 results
    it settles pricing, volumes and rollout pace against central lab testing.
  • US digital pathology ramp FY27 loss-making; meaningful FY28-29
    it shows hospital conversions and burn against the $30m funding.
  • New R&D centre at Bengaluru Jun 2028
    it brings the integrated centre online for the larger research team.
  • Automation at existing plants No timeline; deployment underway
    it enables about twice FY26 topline. Utilisation lift will show it.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
926
52W Range
High
1687
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

6 Yes

Positive for this company

4 Neutral

Neutral for this company

3 No

Negative for this company

4 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Asset Break-Up - Geography Wise

Operational Metrics

    Select a Metric
    • Annual Sales Volume - Test Kits (No)

    Peer Comparison

    FAQs on Molbio Diagnostics Ltd. Business

    Molbio Diagnostics Limited, incorporated in 2000, is engaged in developing, manufacturing and commercializing point-of-care molecular diagnostic solutions. The company operates in the healthcare diagnostics segment, offering rapid testing solutions for infectious and non-communicable diseases through its Truenat platform.

    Molbio Diagnostics major competitors are Poly Medicure, Dr. Lal Pathlabs, Metropolis Health., Vijaya Diagnostic.
    Market Cap of Molbio Diagnostics is ₹17,460 Crs.
    While the median market cap of its peers are ₹15,660 Crs.

    Molbio Diagnostics seems to be less financially stable compared to its competitors.
    Altman Z score of Molbio Diagnostics is 12.87 and is ranked 4 out of its 5 competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release
    Investor Presentation Sep
    Conference Call Sep
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    []
    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material